BOAT: Beta Blocker Uptitration With OptiVol After Cardiac

Status Terminated

Clinical Trial Summary

Many heart failure patients are unable to reach target beta blocker doses. This study will address whether cardiac resynchronization therapy (CRT) will enable uptitration of beta-blockers to target doses and whether it will favorably affect remodeling by reducing left ventricular end systolic volume (LVESV), with measurable clinical benefit, beyond CRT alone (without changes in beta-blocker dose).

Clinical Trial Description

Beta blockers have been proven to have benefit in heart failure (HF) patients with regard to morbidity and mortality. However, initiation and uptitration remains a challenge in many patients. Worsening of heart failure, symptomatic hypotension and symptomatic bradycardia all limit up-titration to the target doses that have been shown to have mortality benefits (carvedilol [Coreg] 25 mg bid, metoprolol succinate [Toprol-XL] 200 mg qd) in the large clinical trials (COPERNICUS, MERIT-HF).

It is debated whether the benefit of beta-blockade is solely due to heart rate reduction or more broadly from the cardiac, central and peripheral effects of blocking sympathetic activity. Clearly, there is a remodeling effect on the dilated ventricle. Furthermore, patients with heart rates of 64 bpm or less are rarely begun on beta-blocker therapy. It is not known whether these patients should be given a pacemaker in order to then safely initiate beta-blocker therapy.

It is also clear that isolated right ventricular pacing can have deleterious effects on ventricular dyssynchrony and symptomatic heart failure despite medical therapy. Biventricular pacing (BIVPM), also known as cardiac resynchronization therapy (CRT), is the pacing mode of choice for patients with wide QRS complexes and symptomatic HF.

It is hypothesized that CRT therapy allows for increased Beta -blocker dose (or initiation of beta-blocker in patients previously intolerant) with improved NYHA, ejection fraction, and remodeling effects. The synergy between two established heart failure therapies requires further evaluation in a prospective randomized trial. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00433043
Study type	Interventional
Source	St. Luke's-Roosevelt Hospital Center
Contact
Status	Terminated
Phase	Phase 4
Start date	January 2007
Completion date	May 2009

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04115735` - His Bundle Recording From Subclavian Vein
Recruiting	`NCT05562037` - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA	N/A
Completed	`NCT05563701` - Evaluation of the LVivo Image Quality Scoring (IQS)
Recruiting	`NCT05865184` - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed	`NCT04037436` - Functional Exercise and Nutrition Education Program for Older Adults	N/A
Recruiting	`NCT04703842` - Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction	Phase 1/Phase 2
Terminated	`NCT05594940` - Heart Failure Monitoring With a Portable Ultrasound Device With Artificial Intelligence Assisted Tools: A Multi-Phase Observational Feasibility Study
Recruiting	`NCT04982081` - Treating Congestive HF With hiPSC-CMs Through Endocardial Injection	Phase 1
Completed	`NCT04394754` - Evaluating Efficacy of Digital Health Technology in the Treatment of Congestive Heart Failure	N/A
Active, not recruiting	`NCT01385176` - Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF)	N/A
Not yet recruiting	`NCT05516290` - Evaluating Clinical Trial Experiences of Individuals With Congestive Heart Failure
Terminated	`NCT02788656` - Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)	Phase 4
Completed	`NCT02885636` - Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial	Phase 3
Terminated	`NCT02205411` - Clinical Trial to Evaluate the the ReliantHeart HeartAssist 5® VAD System in Patients Awaiting Heart Transplantation	N/A
Completed	`NCT02252757` - Assess Measurements of Wireless Cardiac Output Device	N/A
Completed	`NCT01362855` - Advance Care Planning Evaluation in Hospitalized Elderly Patients
Withdrawn	`NCT00346177` - Stem Cell Study for Patients With Heart Failure	Phase 2
Completed	`NCT01476995` - Prognostic Indicators as Provided by the EPIC ClearView	N/A
Active, not recruiting	`NCT01058837` - SCD-HeFT 10 Year Follow-up	N/A
Completed	`NCT00957541` - Evaluation of a Diagnostic Feature in a Cardiac Resynchronization Therapy (CRT) Device	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

BOAT: Beta Blocker Uptitration With OptiVol After Cardiac Resynchronization Therapy (CRT)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms